MiraDx Reaps $1M Investment From Connecticut Innovations | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MircoRNA test developer MiraDx has received a $1 million investment through the Eli Whitney Fund of Connecticut Innovations, a technology-focused economic development group, CI said today.

For the firm, which is based in New Haven, Conn., the $1 million investment is part of its Series A round of financing that will add up to a total of $4 million, CI said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.